Now Reading
Abbott's Global Sustainability Report shares how we're focused on helping more people, now and in the years ahead.
Abbott's Global Sustainability Report shares how we're focused on helping more people, now and in the years ahead.
Published 14 hours ago
Submitted by Abbott
Abbott
At Abbott, we've embedded sustainability across our business – which is helping us to deliver solid progress toward the goals we set in our 2030 Sustainability Plan. From our priority of innovating for greater access in health, to protecting a healthy environment, to building the diverse, innovative workforce of tomorrow, our 2023 Global Sustainability Report highlights progress toward our goal of improving the lives of 3 billion people each year by the end of the decade.
Innovating for Access and Equity
Innovation without access is meaningless. This is why we work so hard to ingrain access and affordability into our products at every stage of development and remove the barriers that stand in the way of good health, evolving the way we invent and bring technologies to the people who need them. A few highlights of our work in 2023:
Reducing Our Environmental Footprint
Advancing health also means doing our part to improve the health of the planet. Across Abbott, we completed 102 projects to help address our environmental impacts at 45 sites across 20 countries. We achieved a 7% reduction in Scope 1 and 2 emissions, making good progress toward our goal of a 30% reduction from our 2018 baseline, and established a $15 million annual environmental sustainability capital fund to support energy efficiency projects. We reduced our water use by 3% overall, and we tripled the number of high-water-impact sites in water-stressed areas that have achieved Alliance for Water Stewardship (AWS) certification, adding four sites for a total of six to date. We also diverted 91% of our operational waste from landfills and increased the number of sites sending zero-waste-to-landfill to 53 globally.
Building the Workforce of Tomorrow
Our ability to build a healthy, sustainable future depends on the innovative ideas, execution and dedication of our global workforce, and this year's report shares updates those efforts. In our original 2030 plan, we had targets to create 1 million development and job opportunities for current and future employees, and to create opportunities in STEM programs and internships for 100,000 young people. In 2023, we were already exceeding our expected progress – so we’re now doubling those goals for 2030.
See our full 2023 Global Sustainability Report for more details on these areas – and to learn more about how we responsibly connect data, technology and care, strengthen our global supply chain and ensure product quality.
IMPORTANT SAFETY INFORMATION
AVEIR™ DR
Rx Only
Brief Summary: Prior to using these devices, please review the Instructions for Use for a complete listing of indications, contraindications, warnings, precautions, potential adverse events and directions for use.
Indications: The Aveir™ Leadless Pacemaker system is indicated for management of one or more of the following permanent conditions: Syncope, Pre-syncope, Fatigue, Disorientation. Rate-modulated pacing is indicated for patients with chronotropic incompetence, and for those who would benefit from increased stimulation rates concurrent with physical activity. Dual-chamber pacing is indicated for patients exhibiting: Sick sinus syndrome, Chronic, symptomatic second- and third-degree AV block, Recurrent Adams-Stokes syndrome, Symptomatic bilateral bundle-branch block when tachyarrhythmia and other causes have been ruled out. Atrial pacing is indicated for patients with: Sinus node dysfunction and normal AV and intraventricular conduction systems. Ventricular pacing is indicated for patients with: Significant bradycardia and normal sinus rhythm with only rare episodes of AV block or sinus arrest, Chronic atrial fibrillation, Severe physical disability.
Intended Use: The Aveir™ Leadless Pacemaker (LP) is designed to provide bradycardia pacing as a pulse generator with built-in battery and electrodes for implantation in the right ventricle and/or right atrium. The LP is intended to provide sensing of intrinsic cardiac signals and delivery of cardiac pacing therapy within the implanted chamber for the target treatment group. The LP is also intended to operate optionally with another co-implanted LP to provide dual-chamber pacing therapy.
The Aveir™ Delivery Catheter is intended to be used in the peripheral vasculature and the cardiovascular system to deliver and manipulate an LP. Delivery and manipulation includes implanting an LP within the target chamber of the heart.
Contraindications: Use of the Aveir™ Leadless Pacemaker is contraindicated in these cases:
Adverse Events: Potential complications associated with the use of the Aveir™ Leadless Pacemaker system are the same as with the use of single or dual chamber pacemakers with active fixation pacing leads including, but not limited to: Cardiac perforation, Cardiac tamponade, Pericardial effusion, Pericarditis, Valve damage and/or regurgitation, Heart failure, Pneumothorax/hemothorax, Cardiac arrhythmias, Diaphragmatic/phrenic nerve stimulation / extra-cardiac stimulation, Palpitations, Hypotension, Syncope, Cerebrovascular accident, Infection, Hypersensitivity reaction to device materials, contrast media, medications, or direct toxic effect of contrast media on kidney function, Pacemaker syndrome, Inability to interrogate or program the LP due to programmer or LP malfunction, Intermittent or complete loss of pacing and/or sensing due to dislodgement or mechanical malfunction of the LP (non-battery related), Loss of capture or sensing due to embolization or fibrotic tissue response at the electrode, Increased capture threshold, Inappropriate sensor response, Interruption of desired LP function due to electrical interference, either electromyogenic or electromagnetic, Battery malfunction/ premature battery depletion, Device-related complications (Premature deployment, Device dislodgement/embolization of foreign material, Helix distortion), Death. As with any percutaneous catheterization procedure, potential complications include, but are not limited to: Vascular access complications; such as perforation, dissection, puncture, groin pain, Bleeding or hematoma, Thrombus formation, Thromboembolism, Air embolism, Local and systemic infection, Peripheral nerve damage. General surgery risks and complications from comorbidities; such as hypotension, dyspnea, respiratory failure, syncope, pneumonia, hypertension, cardiac failure, reaction to sedation, renal failure, anemia, and death.
MAT-2306873 v1.0 | Item is approved for US Use
About Abbott and the Abbott Fund
The Abbott Fund is a philanthropic foundation established by Abbott in 1951. The Abbott Fund's mission is to create healthier global communities by investing in creative ideas that promote science, expand access to health care and strengthen communities worldwide. For more information, visit www.abbottfund.org.
Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs nearly 90,000 people and markets its products in more than 130 countries. Abbott's news releases and other information are available on the company's website at www.abbott.com.
More from Abbott